Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension

Drugs

Volumn 54, Issue 6, 1997, Pages 885-902

  Gillis, Jane C ^a   Markham, Anthony ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; ENALAPRIL; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; RECEPTOR SUBTYPE;

ADULT; AGE; AGED; ANTIHYPERTENSIVE ACTIVITY; AREA UNDER THE CURVE; BLOOD PRESSURE REGULATION; BONE PAIN; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EXCRETION; DRUG METABOLISM; DRUG STRUCTURE; FATIGUE; FEMALE; HEADACHE; HEART FAILURE; HEMODYNAMICS; HUMAN; HYPERTENSION; INFLUENZA; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MYALGIA; NAUSEA; ORAL DRUG ADMINISTRATION; PHARYNGITIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SEX DIFFERENCE; UPPER RESPIRATORY TRACT INFECTION; VERTIGO;

EID: 0030694110     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199754060-00007     Document Type: Review

References (60)

1. Velasquez MT. Angiotensin II receptor blockers. A new class of antihypertensive drugs. Arch Fam Med 1996 Jun; 5: 351-6
2. Bauer JH, Reams GP. The angiotensin II type 1 receptor antagonists. A new class of antihypertensive drugs. Arch Intern Med 1995 Jul 10; 155: 1361-8
3. Timmermans PBMWM, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45 (2): 205-51
4. Timmermans PBMWM, Smith RD. Angiotensin II receptor subtypes: selective antagonists and functional correlates. Eur Heart J 1994 Dec; 15 Suppl. D: 79-87
5. 1 subtype antiotensin II receptor antagonist. J Pharmacol Exp Ther 1993 May; 265: 826-34
6. 3H]SR 47436. Eur J Pharmacol 1993 Oct 15; 247: 139-44
7. 1 receptor antagonist irbesartan in hypertension. Hypertension 1995; 25: 22-9
8. Ribstein J, Sissmann J, Picard A, et al. Pressor response to angiotensin II in sodium replete normal subjects and its blockade by the angiotensin II antagonist SR 47436 (BMS 186295) [abstract]. Am J Hypertens 1995 Apr; 8 (Pt 2): 185
9. Ribstein J, Mimran A, Sissmann J, et al. Assessment of the inhibition of pressor response to exogenous angiotensin II (AII) by single-dose irbesartan (75, 150, 300mg) in normotensive subjects. Eighth European Meeting on Hypertension; 13-16 Jun, 1997; Milan, Italy
10. Sissmann J, Bouroudian M, Armagnac C, et al. Angiotensin II blockade in healthy volunteers: tolerability and impact on renin angiotensin system components of single and repeated doses of a new angiotensin II receptor antagonist SR 47436 (BMS 186295) [abstract]. J Hypertens 1994 Mar; 12 Suppl. 3: 92
11. Marino MR, Langenbacher K, Ford NF, et al. Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects. Clin Pharmacol Ther. In press
12. McIntyre M, MacFadyen RJ, Meredith PA. Dose-ranging study of the angiotensin II receptor antagonist irbesartan (SR 47436/BMS-186295) on blood pressure and neurohormonal effects in salt-deplete men. J Cardiovasc Pharmacol 1996 Jul; 28: 101-6
13. Hagmann M, Burnier M, Nussberger J, et al. Natriuretic and hormonal effects of SR 47436 (BMS 186295), a new angiotensin II receptor antagonist in normotensive volunteers [abstract]. Am J Hypertens 1994 Apr; 7 (Pt 2): 13A
14. Sica DA, Marino MR, Hammett JL, et al. The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysis. Clin Pharmacol Ther. In press
15. Marino MR, Langenbacher KM, Raymond RH, et al. Pharmacokinetics and pharmacodynamics of irbesartan in subjects with hepatic cirrhosis. J Clin Pharmacol. In press
16. Marino MR, Langenbacher KM, Ford NF, et al. Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of irbesartan [abstract]. Clin Pharmacol Ther 1997; 61 (2): 207
17. van den Meiracker AH, de Bruin RJA, Derkx FHM, et al. Effect of the AT1-receptor antagonist irbesartan on plasma angiotensinogen concentration [abstract 861]. Proceedings from the Seventh European Meeting on Hypertension 1995 Jun 9: 195
18. Burnier M, Hagman M, Nussberger J, et al. Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects. Hypertension 1995 Apr; 25 (Pt 1): 602-9
19. Pool JL, Guthrie RM, Littlejohn III TW, et al. Dose-related effects of irbesartan in patients with mild-to-moderate hypertension. Am J Hypertens. In press
20. Goa KL, Wagstaff AJ. Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Drugs 1996 May; 51: 820-45
21. Pohl M, Cooper M, Ulrey J, et al. Safety and efficacy of irbesartan in hypertensive patients with type II diabetes and proteinuria [abstract D4]. Am J Hypertens 1997; 10 (4 Pt 2): 105A
22. Rosendorff C. The renin-angiotensin system and vascular hypertrophy. J Am Coll Cardiol 1996 Oct; 28: 803-12
23. Regitz-Zagrosek V, Neuss M, Fleck E. Effects of angiotensin receptor antagonists in heart failure: clinical and experimental aspects. Eur Heart J 1995 Dec; 16 Suppl. N: 86-91
24. Regitz-Zagrosek V, Neuss M, Holzmeister J, et al. Use of angiotensin II antagonists in human heart failure: function of the subtype I receptor. J Hypertens 1995 Jul; 13 Suppl. 1: S63-71
25. 1 receptor antagonist, on human vascular smooth muscle cells in vitro. Eur J Pharmacol 1994 Jan 14; 251: 143-50
26. Vacher E, Fornes P, Richer C. Early and late haemodynamic and morphological effects of angiotensin II subtype 1 receptor blockade during genetic hypertension development. J Hypertens 1995 Jun; 13: 675-82
27. Spinale FG, Holzgrefe HH, Hird RB, et al. Differential effects of angiotensin converting enzyme (ACE) inhibition and AT1 angiotensin-II receptor (ATI AT-II) blockade on LV and myocyte function and structure with dilated cardiomyopathy (OCM) [abstract]. Circulation 1994 Oct; 90 (Pt 2): 111
28. Stumpe KO, Haworth D, Höglund C, et al. Comparison of the angiotensin II receptor antagonist irbesartan with atenolol for treatment of hypertension. Blood Press. In press
29. LeJemtel T, Awan N, Liang C-s, et al. Irbesartan - a new angiotensin II antagonist: acute hemodynamic effects in patients with heart failure [abstract]. Circulation 1996 Oct 15; 94 Suppl.: 622-3
30. Vachharajani N, Chang S-Y, Shyu WC. Absolute bioavailability of irbesartan. an angiotensin II receptor antagonist, in man [abstract]. Pharm Res 1995 Sep; 12 Suppl.: 418
31. Vachharajani N, Shyu WC, Smith R, et al. The effects of age and gender on the pharmacokinetics of irbesartan [abstract]. Pharm Res 1995 Sep; 12 Suppl.: 388
32. Necciari J, Denolle T, Le Coz F, et al. Pharmacokinetics of SR 47436 (BMS 186295), a new angiotensin II receptor antagonist in man [abstract]. J Hypertens 1994 Mar; 12 Suppl. 3: 88
33. Chando TJ, Everett DW, Kahle AD, et al. Biotransformation of irbesartan in man. 1997; Data on file, Bristol-Myers Squibb
34. Marino MR, Langenbacher KM, Raymond RH, et al. Pharmacokinetics (PK) and antihypertensive effects of irbesartan (an AII receptor antagonist) in subjects with hypertension [abstract]. Hypertension 1996; 14 Suppl. 1: S348
35. Guthrie R, Saini R, Herman T, et al. Efficacy and safety of irbesartan, the angiotensin II receptor antagonist, in essential hypertension. Am J Med. In press
36. Fogari R, Ambrosoli S, Corradi L, et al. 24-hour blood pressure control by once-daily irbesartan as assessed by ambulatory blood pressure monitoring. J Hypertens. In press
37. Meredith PA. Trough/peak ratios for antihypertensive agents: the issues in perspective. Drugs 1994; 48 (5): 661-6
38. Kochar M, Zablocki CJ, Guthrie R, et al. Irbesartan in combination with hydrochlorothiazide in mild-to-moderate hypertension [abstract D5]. Am J Hypertens 1997; 10 (4 Pt 2): 106A
39. Kassler-Taub K, Proszynski B, Zanoni L, et al. Comparative efficacy and tolerability of irbesartan versus losartan in mild to moderate hypertension [abstract]. American Heart Association, 70th Scientific Sessions
40. Mimran A, Ruilope L, Kerwin L, et al. A randomized, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension. 1997; Data on File. Bristol Myers Squibb
41. Larochelle P, Flack JM, Marbury TC, et al. Antihypertensive effects and tolerability of irbesartan versus enalapril: a randomized trial in patients with severe hypertension. Am J Cardiol. In press
42. Littlejohn T, Saini RK, Badiak H, et al. Long-term safety and antihypertensive efficacy of irbesartan, the angiotensin II receptor antagonist: pooled results of six open-label studies [abstract D56]. Am J Hypertens 1997; 10 (4 Pt 2): 119A
43. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995 May 10; 273 (18): 1450-6
44. Tonkon M, Awan N, Niazi I, et al. Combination of irbesartan with conventional therapy, including angiotensin converting enzyme inhibitors [abstract]. Heart failure '97; 1997 May 24-27; Cologne
45. Vijay N, Alhaddad IA, Denny DM, et al. Irbesartan compared with lisinopril in heart failure [abstract]. Heart failure '97: 1997 May 24-27; Cologne
46. Simon TA, Gelarden RT, Freitag SA, et al. The safety of irbesartan in the treatment of mild-to-moderate hypertension: results of 9 randomized, double-blind, placebo-controlled studies. Bristol-Myers Squibb, 1997. (Data on file)
47. Lacourcière Y, Lefebvre J. Modulation of the renin-angiotensin-aldosterone system and cough. Can J Cardiol 1995 Aug: 11 Suppl. F: 33F-9F
48. Irbesartan prescribing information. Bristol-Myers Squibb Pharma EEIG, Ickenham, England
49. Chalmers J, Zanchetti A. The 1996 report of a World Health Organization expert committee on hypertension control. J Hypertens 1996 Aug; 14: 929-33
50. Zanchetti A, Chalmers J, Arakawa K, et al. Summary of 1993 World Health Organisation-International Society of Hypertension guidelines for the management of mild hypertension. BMJ 1993 Dec 11; 307: 1541-6
51. Joint National Committee on Detection Evaluation and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on detection, evaluation, and treatment of high blood pressure (JNC V). Arch Intern Med 1993 Jan 25; 153: 154-83
52. Kaplan NM, Gifford Jr RW. Choice of initial therapy for hypertension. JAMA 1996 May 22-29; 275: 1577-80
53. Dworkin LD. Impact of antihypertensive therapy on progression of experimental renal disease. J Hum Hypertens 1996 Oct; 10: 663-8
54. Freis ED, Papademetriou V. Current drug treatment and treatment patterns with antihypertensive drugs. Drugs 1996 Jul; 52: 1-16
55. Navis G, Faber HJ, de Zeeuw D, et al. ACE inhibitors and the kidney: a risk-benefit assessment. Drug Saf 1996 Sep; 15 (3): 200-11
56. Hollenberg NK, Fisher NDL. Renal circulation and blockade of the renin-angiotensin system: is angiotensin-converting enzyme inhibition the last word? Hypertension 1995 Oct; 26: 602-9
57. Jover B, Mimran A. Angiotensin II receptor antagonists versus angiotensin converting enzyme inhibitors: effects on renal function. J Hypertens 1994 Nov; 12 Suppl. 9: S3-9
58. Bonarjee VVS, Dickstein K. Novel drugs and current therapeutic approaches in the treatment of heart failure. Drugs 1996 Mar; 51: 347-58
59. Dahlöf B. Effect of angiotensin II blockade on cardiac hypertrophy and remodelling: a review. J Hum Hypertens 1995 Nov; 9 Suppl. 5: 37-44
60. Lüscher TF, Yang Z. Calcium antagonists and ACE inhibitors. Effects on endothelium and vascular smooth muscle. Drugs 1993; 46 Suppl. 2: 121-32